Page 3 - மருந்துகள் வைத்திருத்தல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மருந்துகள் வைத்திருத்தல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மருந்துகள் வைத்திருத்தல் Today - Breaking & Trending Today

Tonix Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Highlights

Share:
Interim Analysis of Second Confirmatory Phase 3 Study in Fibromyalgia
Expected in Third Quarter 2021
Deep Pipeline Progressing with Three Central Nervous System
(CNS) Programs Expected to Enter Phase 2 Trials This Year
At March 31, 2021, Cash and Cash Equivalents Totaled Approximately $164 Million
CHATHAM, N.J., May 10, 2021 (GLOBE NEWSWIRE) Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2021 and provided an overview of recent operational highlights.
Tonix possesses a deep pipeline of high-value programs ranging from preclinical to mid-Phase 3 development, with three CNS programs poised to enter Phase 2 trials this year, said Seth Lederman, M.D., President and Chief Executive Officer. Our strategy is to in-license, acquire or internally invent high impact therapeutic programs which we can valid ....

United States , Rydyznski Moderbacher , Jessica Morris , Seth Lederman , Olipriya Das , Le Bert , Peter Vozzo , Us National Cancer Institute , Tonix Pharmaceuticals , French National Institute Of Health , Harvard Medical School Teaching Hospital Massachusetts , Drug Administration , Exchange Commission , Tonix Pharmaceuticals Holding Corp , Oyagen Inc , Announced Positive Efficacy Data , Animal Studies , Second Confirmatory Phase , Third Quarter , Pipeline Progressing , Three Central Nervous System , Programs Expected , Center Phase , Cash Equivalents Totaled Approximately , Pharmaceuticals Holding , Chief Executive ,

Santhera Announces First Trading Day of New Convertible Bonds on SIX Swiss Exchange

is starting today
on the SIX Swiss Exchange.
On May 4, 2021, Santhera Pharmaceuticals Holding AG issued Senior Unsecured Convertible Bonds due 2024 (the
2021/24 Bonds) in the aggregate principal amount of CHF 30,270,375. The 2021/24 Bonds have been admitted to trading on the SIX Swiss Exchange. The first trading day is today, May 7, 2021. The ticker symbol of the 2021/24 Bonds is SAN21 and ISIN CH0563348744.
As set out in the terms and conditions [1], the conversion period during which a bondholder may exercise the conversion rights for the 2021/24 Bonds has started on May 4, 2021, and ends seven trading days before the maturity date on August 17, 2024 (or, in case of early redemption, ten trading days prior to the date fixed for early redemption). ....

Switzerland General , United States , United Kingdom , Eva Kalias , Santhera Pharmaceuticals , Head External Communications , Swiss Exchange , Santhera Pharmaceuticals Holding , Swiss Financial Services , Chiesi Group , Exchange Regulation Ltd , Unsecured Convertible Bonds , Senior Unsecured Convertible Bonds , Regulation Ltd , Swiss Financial Services Act , Annual General , North American , Head External , Pharmaceuticals Holding , சுவிட்சர்லாந்து ஜநரல் , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , சந்தேற மருந்துகள் , தலை வெளிப்புறம் தகவல்தொடர்புகள் , சுவிஸ் பரிமாற்றம் , சந்தேற மருந்துகள் வைத்திருத்தல் ,

Santhera Announces Settlement of Exchange Offer and Issuance of New Senior Unsecured Convertible Bonds due 2024

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO
Pratteln, Switzerland, May 4, 2021 – Santhera . ....

Switzerland General , United States , United Kingdom , Eva Kalias , Basler Kantonalbank , Santhera Pharmaceuticals , Swiss Financial Services Act Fin , Head External Communications , Financial Services , Santhera Pharmaceuticals Holding , Us Securities Exchange , Stifel Nicolaus Europe , European Union Withdrawal , Chiesi Group , Exchange Regulation Ltd , Convertible Bonds , Unsecured Convertible Bonds , Repurchase Offer , Senior Unsecured Convertible Bonds , Exchange Offer , Regulation Ltd , Nicolaus Europe Limited , Listing Prospectus Regarding , New Bonds , Annual General , North American ,

Santhera Pharmaceuticals Holding AG: Santhera Announces Settlement of Exchange Offer and Issuance of New Senior Unsecured Convertible Bonds due 2024

Santhera Pharmaceuticals Holding AG: Santhera Announces Settlement of Exchange Offer and Issuance of New Senior Unsecured Convertible Bonds due 2024
Pratteln, Switzerland,
s the settlement of the
e
.
Santhera Pharmaceuticals Holding AG is settling today its offer to exchange its outstanding CHF 60 million 5% Convertible Bonds due 2022 (the
2017/22 Bonds) on the terms set out in the Notice of Repurchase Offer dated March 25, 2021 (the
Exchange
Offer). Upon settlement, 2017/22 Bonds in the aggregate principal amount of CHF 15,155,000 remain in circulation.
Santhera will issue today Senior Unsecured Convertible Bonds due 2024 (the
2021/24 Bonds) in the aggregate principal amount of CHF 30,270,375, on the terms set out in the issuance and listing prospectus dated May 4, 2021, to those holders of the 2017/22 Bonds who accepted the Exchange Offer. The principal amount/denomination of the 2021/24 Bonds is CHF 3,375 per bond, with a conversion ....

Switzerland General , United States , United Kingdom , Eva Kalias , Basler Kantonalbank , Santhera Pharmaceuticals , Head External Communications , Financial Services , Santhera Pharmaceuticals Holding , Swiss Financial Services , Us Securities Exchange , Stifel Nicolaus Europe , European Union Withdrawal , Exchange Regulation Ltd , Convertible Bonds , Unsecured Convertible Bonds , Repurchase Offer , Senior Unsecured Convertible Bonds , Exchange Offer , Regulation Ltd , Nicolaus Europe Limited , Listing Prospectus Regarding , New Bonds , Head External , Pharmaceuticals Holding , Exchange Act ,